303 related articles for article (PubMed ID: 32439933)
1. Translating current basic research into future therapies for neurofibromatosis type 1.
Brosseau JP; Liao CP; Le LQ
Br J Cancer; 2020 Jul; 123(2):178-186. PubMed ID: 32439933
[TBL] [Abstract][Full Text] [Related]
2. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.
Gottfried ON; Viskochil DH; Couldwell WT
Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723
[TBL] [Abstract][Full Text] [Related]
3. Pathogenesis of plexiform neurofibroma: tumor-stromal/hematopoietic interactions in tumor progression.
Staser K; Yang FC; Clapp DW
Annu Rev Pathol; 2012; 7():469-95. PubMed ID: 22077553
[TBL] [Abstract][Full Text] [Related]
4. Spatiotemporal Loss of
Chen Z; Mo J; Brosseau JP; Shipman T; Wang Y; Liao CP; Cooper JM; Allaway RJ; Gosline SJC; Guinney J; Carroll TJ; Le LQ
Cancer Discov; 2019 Jan; 9(1):114-129. PubMed ID: 30348677
[TBL] [Abstract][Full Text] [Related]
5. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
[TBL] [Abstract][Full Text] [Related]
6. A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.
Ratner N; Miller SJ
Nat Rev Cancer; 2015 May; 15(5):290-301. PubMed ID: 25877329
[TBL] [Abstract][Full Text] [Related]
7. Genetic analyses of mosaic neurofibromatosis type 1 with giant café-au-lait macule, plexiform neurofibroma and multiple melanocytic nevi.
Hida T; Idogawa M; Okura M; Sugita S; Sugawara T; Sasaki Y; Tokino T; Yamashita T; Uhara H
J Dermatol; 2020 Jun; 47(6):658-662. PubMed ID: 32246533
[TBL] [Abstract][Full Text] [Related]
8. The primacy of NF1 loss as the driver of tumorigenesis in neurofibromatosis type 1-associated plexiform neurofibromas.
Pemov A; Li H; Patidar R; Hansen NF; Sindiri S; Hartley SW; Wei JS; Elkahloun A; Chandrasekharappa SC; ; Boland JF; Bass S; ; Mullikin JC; Khan J; Widemann BC; Wallace MR; Stewart DR
Oncogene; 2017 Jun; 36(22):3168-3177. PubMed ID: 28068329
[TBL] [Abstract][Full Text] [Related]
9. The role of nerve microenvironment for neurofibroma development.
Liao CP; Pradhan S; Chen Z; Patel AJ; Booker RC; Le LQ
Oncotarget; 2016 Sep; 7(38):61500-61508. PubMed ID: 27517146
[TBL] [Abstract][Full Text] [Related]
10. Plexiform neurofibroma genesis: questions of Nf1 gene dose and hyperactive mast cells.
Staser K; Yang FC; Clapp DW
Curr Opin Hematol; 2010 Jul; 17(4):287-93. PubMed ID: 20571392
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous neurofibromas in the genomics era: current understanding and open questions.
Allaway RJ; Gosline SJC; La Rosa S; Knight P; Bakker A; Guinney J; Le LQ
Br J Cancer; 2018 Jun; 118(12):1539-1548. PubMed ID: 29695767
[TBL] [Abstract][Full Text] [Related]
12. New Model Systems and the Development of Targeted Therapies for the Treatment of Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors.
Williams KB; Largaespada DA
Genes (Basel); 2020 Apr; 11(5):. PubMed ID: 32353955
[TBL] [Abstract][Full Text] [Related]
13. Concomitant variants in NF1, LZTR1 and GNAZ genes probably contribute to the aggressiveness of plexiform neurofibroma and warrant treatment with MEK inhibitor.
Cohen-Barak E; Toledano-Alhadef H; Danial-Farran N; Livneh I; Mwassi B; Hriesh M; Zagairy F; Gafni-Amsalem C; Bashir H; Khayat M; Warrour N; Sher O; Marom D; Postovsky S; Dujovny T; Ziv M; Shalev SA
Exp Dermatol; 2022 May; 31(5):775-780. PubMed ID: 34913528
[TBL] [Abstract][Full Text] [Related]
14. Confirmation of mutation landscape of NF1-associated malignant peripheral nerve sheath tumors.
Sohier P; Luscan A; Lloyd A; Ashelford K; Laurendeau I; Briand-Suleau A; Vidaud D; Ortonne N; Pasmant E; Upadhyaya M
Genes Chromosomes Cancer; 2017 May; 56(5):421-426. PubMed ID: 28124441
[TBL] [Abstract][Full Text] [Related]
15. NF1 truncating mutations associated to aggressive clinical phenotype with elephantiasis neuromatosa and solid malignancies.
Ponti G; Martorana D; Pellacani G; Ruini C; Loschi P; Baccarani A; De Santis G; Pollio A; Neri TM; Mandel VD; Maiorana A; Maccio L; Maccaferri M; Tomasi A
Anticancer Res; 2014 Jun; 34(6):3021-30. PubMed ID: 24922668
[TBL] [Abstract][Full Text] [Related]
16. Mosaic Neurofibromatosis Type 1 With Multiple Cutaneous Diffuse and Plexiform Neurofibromas of the Lower Leg.
Friedrich RE; Hagel C; Kohlrusch FK; Schanze I; Wieland I; Zenker M
Anticancer Res; 2020 Jun; 40(6):3423-3427. PubMed ID: 32487640
[TBL] [Abstract][Full Text] [Related]
17. The role of the immune system in neurofibromatosis type 1-associated nervous system tumors.
Karmakar S; Reilly KM
CNS Oncol; 2017 Jan; 6(1):45-60. PubMed ID: 28001089
[TBL] [Abstract][Full Text] [Related]
18. The promise of signal transduction in genetically driven sarcomas of the nerve.
Kim A; Pratilas CA
Exp Neurol; 2018 Jan; 299(Pt B):317-325. PubMed ID: 28859862
[TBL] [Abstract][Full Text] [Related]
19. Reprogramming Captures the Genetic and Tumorigenic Properties of Neurofibromatosis Type 1 Plexiform Neurofibromas.
Carrió M; Mazuelas H; Richaud-Patin Y; Gel B; Terribas E; Rosas I; Jimenez-Delgado S; Biayna J; Vendredy L; Blanco I; Castellanos E; Lázaro C; Raya Á; Serra E
Stem Cell Reports; 2019 Feb; 12(2):411-426. PubMed ID: 30713041
[TBL] [Abstract][Full Text] [Related]
20. Recurrent mutations in the NF1 gene are common among neurofibromatosis type 1 patients.
Ars E; Kruyer H; Morell M; Pros E; Serra E; Ravella A; Estivill X; Lázaro C
J Med Genet; 2003 Jun; 40(6):e82. PubMed ID: 12807981
[No Abstract] [Full Text] [Related]
[Next] [New Search]
